SPCS2

Signal peptidase complex subunit 2

0 patent compounds predicted against SPCS2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

	Compound	Confidence	Supporting neighbours

Germline variants in SPCS2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full SPCS2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to SPCS2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
D-Cycloserine for Serine Palmitoyltransferase Inhibition	PHASE4	COMPLETED
Pharmacogenomic Evaluation of Antihypertensive Responses	PHASE4	COMPLETED
Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia	PHASE2/PHASE3	COMPLETED
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)	PHASE3	UNKNOWN
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders	PHASE2	COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)	PHASE1/PHASE2	RECRUITING
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus	PHASE2	UNKNOWN
PCSK9 Inhibitor Treatment for Patients With SPG5	PHASE1/PHASE2	UNKNOWN
Hydroxychloroquin (HCQ) in chILD of Genetic Defect	nan	COMPLETED
Surfactant Derived Protocol in Heart Failure	nan	COMPLETED
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Genetic Regulation of Surfactant Deficiency	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Consequences of Mutations in the SPG7 Gene at the Heterozygous State	nan	COMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease	nan	RECRUITING
Circadian Rhythms and Sleep in Familial DSPS and ASPS	nan	COMPLETED
Genetic Variants and Regulation of Specialized Pro-resolving Mediator	nan	RECRUITING
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI	nan	UNKNOWN
Natural History Study of Smith-Magenis Syndrome	nan	ACTIVE_NOT_RECRUITING
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED
Genetic Analysis of Hereditary Disorders of Hearing and Balance	nan	COMPLETED
PCD New Gene Discovery	nan	COMPLETED
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact	nan	UNKNOWN
SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP)	nan	COMPLETED
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	nan	COMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SPCS2 binder may also engage these)

Protein	Name	Similarity
Q4R512	—	1.000	Q4R512 →
Q9CYN2	—	1.000	Q9CYN2 →
Q5RAY6	—	0.999	Q5RAY6 →
Q28250	—	0.995	Q28250 →
Q5M8Y1	—	0.994	Q5M8Y1 →
Q5BJI9	—	0.986	Q5BJI9 →
Q28C34	—	0.968	Q28C34 →
Q8IWV8	—	0.968	Q8IWV8 →
Q5RF53	—	0.967	Q5RF53 →
Q8N6S4	—	0.966	Q8N6S4 →
Q6P4P2	—	0.966	Q6P4P2 →
O00507	—	0.966	O00507 →
F1QR43	—	0.965	F1QR43 →
Q5F3F5	—	0.965	Q5F3F5 →
Q5ZMW3	—	0.965	Q5ZMW3 →
Q6TEP1	—	0.965	Q6TEP1 →
O35841	—	0.965	O35841 →
A4GWN3	—	0.965	A4GWN3 →
Q8BWQ6	—	0.964	Q8BWQ6 →
Q8C561	—	0.963	Q8C561 →
Q68DH5	—	0.963	Q68DH5 →
Q5R644	—	0.963	Q5R644 →
Q5ZKG8	—	0.963	Q5ZKG8 →
Q5RAQ5	—	0.963	Q5RAQ5 →
Q8C735	—	0.962	Q8C735 →
Q56A27	—	0.962	Q56A27 →
Q4R8N2	—	0.962	Q4R8N2 →
Q3SYY9	—	0.962	Q3SYY9 →
Q7TPD0	—	0.961	Q7TPD0 →
Q5XIK2	—	0.961	Q5XIK2 →